A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (an Autoimmune Disorder That Destructs Platelets, Blood Cells That Help With Clotting, and Can Lead to Easy or Excessive Bruising and Bleeding)

Condition:   Primary Immune Thrombocytopenia Interventions:   Biological: efgartigimod;   Other: Placebo Sponsor:   argenx BVBA Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials